Anxiety, appetite and bone findings
Following the wider research means giving a null result as much room as an intriguing new signal.
Anxiety during a human experiment
In a 2025 randomized crossover trial involving 95 participants, kisspeptin-54 increased LH but did not significantly alter state anxiety compared with placebo. The group included 63 men and 32 women. Cortisol, blood pressure and heart rate also showed no significant difference.
I appreciate experiments that can put an attractive extension of a story under pressure. The reproductive hormone response established biological activity during this experiment; the anxiety measure still came back without a significant change. A broadly emotional account of kisspeptin has to make room for that.
For me, the result earns a clear sentence of its own. Adding a speculative mood benefit would crowd out what the investigators actually measured. The desire experiments remain interesting, while this anxiety experiment has its own answer.
Food intake in women with overweight or obesity
A human appetite study produced another useful separation. In women with overweight or obesity, intravenous kisspeptin raised LH without changing self-rated hunger or objectively measured food intake compared with the control condition. The population was women, and both the subjective hunger measure and the measured meal were considered.
The meal is the part of the experiment I like best. A theory about appetite eventually has to meet something concrete enough to eat. Here, biological activity and the food-intake result went different ways. That is a productive answer, even if it offers little material for an enthusiastic headline.
The authors argued against a direct appetite-suppressing effect in this population. The scope of that conclusion seems sensible to me: it concerns these women and these measurements. Adding a claim about men or another route of administration would outrun the experiment.
Bone markers in healthy men
The bone experiment moves into a different group and a different kind of measurement. In 26 healthy eugonadal men, acute kisspeptin administration produced a maximal 20.3% rise in total osteocalcin and a 24.3% rise in carboxylated osteocalcin. Eugonadal describes the normal sex-hormone status of the men studied. Osteocalcin was measured as a marker of bone formation.
This is the sort of peripheral finding that makes the wide view rewarding. I had come for reproductive biology and found a question about the skeleton waiting beside it. My excitement is about a possible line of investigation, while the reported outcome remains a change in markers.
Related work in mice and osteoclasts identified a kisspeptin-10 pathway that suppressed bone-resorbing cell activity and prevented bone loss in the studied models. Those animal and cellular findings offer a mechanistic lead. They have a different scope from the acute human marker experiment.
How wide to open the frame
The name Omni could encourage an appetite for benefits everywhere. My version of the wide view gives disagreeing findings room to sit together: an unchanged anxiety measure, a similar meal, and a rise in a bone marker that leaves a larger clinical question open.
I leave this collection impressed by the research and impatient with any larger story that smooths away its awkward edges. Each detour makes the biology less tidy. That untidiness is a reason to stay interested.
For the reproductive experiments, return to testosterone and timing or sexual desire. The reading list groups the source records around the questions they address.